Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13470316 | 0.86 | NR1H2 (0.46) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL15499858 | 0.83 | SMN1; SMN2 (0.37) | HPGDRECQLALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL19243200 | 0.83 | GAA (0.56) | PKMALDH1A1MAPT | |
| SCHEMBL14890810 | 0.81 | GAA (0.35) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL15499869 | 0.81 | REV1 (0.36) | EPHX1MAPTSMN1; SMN2 | |
| SCHEMBL7983498 | 0.80 | KDM4E (0.46) | HPGDRECQLEPHX1KDM4EPKM | |
| SCHEMBL19022363 | 0.80 | HPGD (0.57) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL16604392 | 0.79 | HPGD (0.60) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL6105130 | 0.79 | HPGD (0.60) | HPGDRECQLPTPN2PTPN1PTPN6 | |
| SCHEMBL585955 | 0.79 | KMT2A (0.50) | HPGDRECQLPTPN2PTPN1PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3366678-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION | Newlink Genetics Corporation (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9981973-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981973-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981973-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2018-05-29 | — | — | US | disclosed |
| EP-2976332-B1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION. | NEWLINK GENETICS CORP (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20170260188-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | NEWLINK GENETICS CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-20170260188-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | NEWLINK GENETICS CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-20170260188-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | NEWLINK GENETICS CORPORATION | 2017-09-14 | — | — | US | disclosed |
| US-9617272-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617272-B2 | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization | NEWLINK GENETICS CORPORATION (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2976332-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION | Newlink Genetics Corporation (US) | 2016-01-27 | — | — | EP | disclosed |
| US-20150025110-A1 | 1-CYCLOALKYL- OR 1-HETEROCYCLYL-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-01-22 | — | — | US | disclosed |
| WO-2014159248-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION | NEWLINK GENETICS CORPORATION (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014159248-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF IMMUNOSUPPRESSION MEDIATED BY TRYPTOPHAN METABOLIZATION | NEWLINK GENETICS CORPORATION (US) | 2014-10-02 | — | — | WO | disclosed |
| EP-2771313-A1 | 1-CYCLOALKYL- OR 1-HETEROCYCLYL-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013060653-A1 | 1-CYCLOALKYL- OR 1-HETEROCYCLYL-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-02 | — | — | WO | disclosed |
| US-20130109718-A1 | 1-CYCLOALKYL- OR 1-HETEROCYCLYL-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-6235731-B1 | REDUCING BLOOD LIPIDS, SUGARS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-0915888-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | Takeda Chemical Industries, Ltd. (JP) | 1999-05-19 | — | — | EP | disclosed |
| WO-1997040051-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260188-A1 | Tricyclic Compounds as Inhibitors of Immunosuppression Mediated By Tryptophan Metabolization | IDO1, IDO2, TDO2 | HPGD 191/4885RECQL 3049/4885PTPN2 382/4885 |
| US-20150025110-A1 | 1-CYCLOALKYL- OR 1-HETEROCYCLYL-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | HPGD 624/4885RECQL 3924/4885PTPN2 2334/4885 |
| US-20130109718-A1 | 1-CYCLOALKYL- OR 1-HETEROCYCLYL-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | HPGD 624/4885RECQL 3924/4885PTPN2 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.